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Abstract
Background: Tumour infiltrating lymphocytes (TIL) are generally considered to represent a host immune response directed
against tumour antigens. TIL are also increasingly recognised as possible prognostic parameters. However, the effects observed
are variable indicating that results cannot be extrapolated from type of tumour to another. Moreover, it has been suggested that
primary solid tumours may be ignored by the immune system and that a meaningful immune response is only mounted in regional
lymph nodes.
Methods: We have examined the local distribution of immune cells in tumour-related compartments in head and neck
squamous cell carcinomas (HNSCC). In a second step, the prognostic impact of these cells on disease-free survival (DFS) was
analysed. A total of 198 tissue cores from 33 patients were evaluated using tissue mircroarray technique and
immunohistochemistry. Tumour-infiltrating immune cells were identified using antibodies specific for CD3, CD8, GranzymeB,
FoxP3, CD20 and CD68 and quantified using an image analysis system.
Results: We demonstrate a relative expansion of FoxP3+ regulatory T-cells (Treg) and of cytotoxic T-cells among tumour
infitrating T-cells. We also show that intratumoural CD20+ B-cells are significantly more frequent in metastatic deposits than in
primary tumours. Furthermore, we observed a reduced number of peritumoural CD8+ T-cells in metastatic lymph nodes as
compared to univolved regional nodes suggesting a local down-modulation of cellular immunity. All other immune cells did not
show significant alterations in distribution. We did not observe an association of tumour infiltrating immune cells at the primary
site with outcome. However, increased numbers of intraepithelial CD8+ TIL in metastatic tumours as well as large numbers of
peritumoural B-cells in lymph node metastases were associated with favourable outcome. Unexpectedly, no effect on patient
outcome was observed for Treg in any compartment.
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Conclusion: Our results suggest that alterations in lymphocyte distribution in regional lymph nodes rather than at the primary
tumour site may be relevant for patient prognosis. Moreover, we demonstrate that in addition to cellular immunity humoral
immune responses may be clinically relevant in anti-tumour immunity.
Background
Tumour-infiltrating lymphocytes (TIL) are generally
thought to represent a host immune response directed
against antigens expressed on tumour cells [1,2]. In partic-
ular, CD8+ cytotoxic T-cells (CTL) are considered to be the
major effector immune cells directed against tumour cells.
This notion is supported by the observation that cytotoxic
TIL are an indicator of favourable prognosis in certain car-
cinomas while tumour-infiltrating regulatory T-cells
(Treg) have been shown to be associated with unfavoura-
ble prognosis in ovarian cancer [3-6]. Tregs have been
characterised as a specialised CD4+CD25+FoxP3+T-cell
population with the ability to inhibit the activity of effec-
tor T-cells. Although it is increasingly recognised that Treg
represent a heterogeneous T-cell population which may
include FoxP3- cells, FoxP3 expression is still considered
the most appropriate single marker for the detection of
Treg in situ and most studies assessing the prognostic rel-
evance of Treg in human cancers rest on the analysis of
FoxP3+ cells (e.g., Gobert et al.) [7].
Studies on TILs have largely focussed on the analysis of
primary tumours. It has been suggested, however, that pri-
mary tumours located outside lymphoreticular tissues
may be largely ignored by the immune system and that
development of a tumour-specific immune response
requires entry of tumour cells into secondary lymphoid
tissues [8]. Recent data suggest that changes in lym-
phocyte distribution may occur in regional tumour-drain-
ing lymph nodes and may play an important role for
prognosis of cancer patients. For example, in patients with
prostatic cancer the immune profile of regional cancer
draining lymph nodes was altered as compared to unin-
volved draining lymph nodes and control nodes obtained
from other sites. Notably, regional metastatic and unin-
volved nodes contained less CD20+  B-cells and more
CD8+ T-cells than control nodes [9]. In gastric carcinomas
an elevated number of Tregs was detected in tumour
draining lymph nodes compared to uninvolved
mesenteric nodes [10]. In early stage breast cancer, senti-
nel and axillary lymph nodes displayed reduced numbers
of CD4+ and CD8+ T-cells as compared to control lymph
nodes while highest numbers of CD1a+ dendritic cells
were seen in uninvolved axillary nodes [11]. Some of
these effects, notably a reduction in the numbers of CD4+
T-cells were observed in draining axillary nodes even in
the absence of metastatic deposits suggesting that altera-
tions of immune profiles in regional lymph nodes may
occur independently of tumour invasion [11]. In that
study, large numbers of CD4+-lymphocytes and of CD1a+-
dendritic cells predicted more precisely for NED-survival
than axillary lymph node metastasis per se indicating an
important functional role of an immune cell distribution
shift [11].
Squamous cell carcinomas of the head and neck region
(HNSCC) represent a group of tumours occuring at vari-
ous sites including the oral mucosa and the palatine ton-
sils. Adding to this diversity is the recent observation that
a proportion of these cancers, notably tonsillar carcino-
mas, are associated with human papillomavirus (HPV)
infection [12]. High density of lymphocytic infiltration
has been identified as favourable specific marker in
HNSCC [13]. Specifically, large numbers of CD3+ T-cells
were associated with favourable outcome in several stud-
ies [14,15]. A specific effect of CD8+ CTL is controversial
[16,17] while a reduction of CD8+  lymphocytes in
regional lymph nodes from HNSCC patients has been
reported [18]. Unexpectedly in one study, FoxP3+ Treg
were associated with improved outcome in HNSCC [16].
Thus, results observed in different cancer models are vari-
able and a clear picture as to the role of TIL has not yet
emerged. It appears, that any analysis of the prognostic
impact of TIL in solid tumours cannot simply rely on the
study of primary tumour samples but has to take other
factors into account such as composition of TIL subsets
and distribution in different anatomical sites related to
the primary tumour. In view of the limited evidence avail-
able in this respect for head and neck squamous cell carci-
noma (HNSCC), the aim of this study was to evaluate
further the morphological distribution and prognostic
impact of regulatory T-cells (FoxP3+), various T-cell sub-
sets (CD3+, CD8+, GranzymeB+), and macrophages
(CD68+) in four different tumour-related compartments,
i.e. primary tumour, lymph node metastases, peritu-
moural area in metastatic lymph nodes and uninvolved
draining lymph nodes of head and neck cancer patients.
Since studies of HNSCC and other cancer have suggested
a beneficial effect of B-cells on outcome [19-21], we also
included B-cells (CD20+) in our analysis.
Methods
Patient Selection
Between 1998 and 2004, a total of 33 patients with histo-
logically proven squamous cell carcinoma of the oro- and
hypopharynx were included in this study. This study was
approved by the ethics committee of the Friedrich-Alexan-BMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
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der-University and informed consent was obtained from
the patients involved. All studies were done on tissue sam-
ples taken for diagnostic or therapeutic purposes and filed
in the archives of the Institute for Pathology, University
Hospital Erlangen. Tissues were not collected specifically
for the purpose of this study. Treatment consisted of resec-
tion of primary tumour as well as a neck dissection fol-
lowed by radiotherapy with (n = 17) and without
chemotherapy (n = 16). Patients were treated in a rand-
omized phase III-trial of postoperative radiation vs. radi-
ochemotherapy. Details of the protocol are given
elsewhere [22].
Briefly, inclusion criteria for enrolment in this study were
as follows:
- squamous cell carcinoma
- primary treatment by radical surgery
- T category: pT4 or pT3 R1 or
- N category:
❍ ≥ 3 pathologically involved lymph nodes or
❍ extracapsular growth of metastasis in N+ nodes
or
❍ lymphangiosis carcinomatosa
All patients were initially assessed by a multidisciplinary
team of head and neck surgeons, radiation oncologists,
medical oncologists and radiologists. Staging procedures
included chest X-ray, liver ultrasound and upper gastroin-
testinal endoscopy as well as tracheoscopy. Both neck
sides and the supraclavicular region were assessed clini-
cally and by ultrasound as well as by histopathological
examination after surgery and neck dissection. Detailed
patient characteristics are displayed in table 1.
Tissue miroarrays and evaluation of tumour infiltrating 
lymphocytes
Paraffin-embedded samples of the primary tumour as
well as of involved and uninvolved lymph nodes available
from 33 patients with oro- and hypopharyngeal squa-
mous cell carcinoma were processed into tissue microar-
rays (BioCat, Heidelberg, Germany) using a core diameter
of 2 mm. Six cores were taken per patient, two cores from
the primary tumour, 2 cores from metastatic deposits in
lymph nodes, 1 core from peritumoural lymphatic tissue
of metastatic (N+) nodes and one core from lymph nodes
without evidence of metastasis, resulting in a total of 198
cores. Immunohistochemistry of paraffin sections was
carried out using a standard streptavidin biotinylated
alkaline phosphatase (ABC-AP, DakoCytomation, Ham-
Table 1: Patient characteristics
n( % )
All patients 33 100
Gender Male 32 (97)
Female 1 (3)
Age (median, 53 years)
36–40 1 (3)
41–50 10 (30)
51–60 15 (46)
61–70 7 (21)
Tumor site Tonsils 8 (24)
Oropharynx 12 (36)
Hypopharynx 5 (16)
Mouth 8 (24)
pTN category T1 N2 7 (21)
T1 N3 1 (3)
T2 N0 1 (3)
T2 N1 2 (6)
T2 N2 5 (16)
T3 N1 1 (3)
T3 N2 5 (16)
T4 N0 1 (3)
T4 N1 1 (3)
T4 N2 6 (19)
TX N1 1 (3)
TX N2 2 (6)
AJCC Stage I0 ( 0 )
II 1 (3)
III 4 (12)
IV 28 (84)
p16 Status positive 10 (31)
negative 22 (69)BMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
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burg, Germany) method or tyramide signal amplification
followed by ABC-AP (only for FoxP3). The following anti-
bodies were used: CD3, CD8, CD20, CD68 and
Granzyme B (all DakoCytomation, Hamburg, Germany)
and FoxP3 (mouse monoclonal, clone 236A/E7, abcam,
Cambridge, UK). p16-specific immunohistochemistry
was carried out using a commercially available kit (mtm
laboratories, Heidelberg, Germany). Cases were scored
positive if the majority of cells demonstrated strong
nuclear staining or negative if no staining was seen or only
a small percentage of tumour cells was labelled. The
results are included in table 1.
By use of a standard light microscope, images were
acquired with a CCD-camera using a 20× objective, trans-
ferred to a PC and semiautomatically evaluated using the
image analysis software COUNT (Biomas, Erlangen, Ger-
many). For quantification purposes, mean numbers of
lymphocytes following the analysis of 3–6 images from
primary and metastatic tumour were taken, respectively.
Specimens of uninvolved draining lymph nodes and per-
itumoural lymphatic tissue from N+ nodes were analyzed
by quantification of 2 images, respectively. Numbers of
labeled tumour-infiltrating cells in primary tumour and
metastatic deposits in N+ nodes were determined using an
image analysis system (Biomas, Erlangen, Germany) in
relation to 100 tumour cells (Labeling index, LI) as
described previously, counting only lymphocytes
admixed with epithelial tumour cells. In uninvolved
lymph nodes and in peritumoural lymphatic tissue of N+
nodes, the number of lymphocytes was quantified per
area of one image (i.e. 0.087 mm2).
The quantitative results for the infiltration of each of these
compartments are displayed in table 2.
Statistical analysis
Disease-free survival (DFS) was the time from initial his-
tological diagnosis until last follow-up or the appearance
of local, nodal or distant recurrence. The correlation
between the infiltration of TILs and other leukocytes in
different compartments was assessed using Pearson corre-
lation procedure. All statistical analyses were performed
with the SPSS for Windows software (Version 15.0). DFS
rates were generated according to the Kaplan-Meier
method. Comparison of survival rates was performed by
use of the log rank test using median numbers as cut-off,
no multivariate analyses were performed due to small
number of events.
Results
Patterns of TIL-infiltration in different compartments
Infiltration of lymphocytes and macrophages was studied
in the following four compartments: (i) primary tumour
(ii) metastatic tumour,(iii) peritumoural areas in meta-
static lymph nodes, and (iv) uninvolved draining lymph
nodes (Figure 1). In primary tumour and metastatic
tumour in regional lymph nodes labeling index, i.e.,
number of intraepithelial cells per 100 tumour cells, was
used to quantify TIL whereas in peritumoural lymphatic
tissue and in uninvolved lymph nodes numbers of lym-
phocytes per area (0.087 mm2) were determined. Overall
the numbers of TIL in primary and metastatic tumour
were similar, and this was also true for the comparison of
peritumoural lymphoreticular tissue in metastatic lymph
nodes and uninvolved lymph nodes (Figure 1a, b, Table
2). However, there were two notable exceptions. Mean
CD20+ cell infiltration was significantly increased in met-
astatic lymph node deposits compared to primary tumour
(p < 0.005) and CD8+ lymphocytes were significantly
more frequent in uninvolved draining nodes compared to
peritumoural lymphatic tissue of metastatic lymph nodes
(p < 0.022). FoxP3+ Treg were similarly frequent in both
tumourous compartments. The ratio of TIL subsets/CD3+
cells was used to compare the infiltration in the four dif-
ferent compartments. Using this approach, we show that,
as a proportion of CD3+ T-cells, tumour infiltrating CD8+
and Granzyme B+ cytotoxic T-cells as well as FoxP3+ Treg
were relatively enriched in primary and metastatic
tumours when compared to uninvolved lymphoid tissue
(Figure 1c).
Prognostic impact of TIL in different tumour 
compartments
As in our previous study [23] the median was used as a
cut-off to separate patient groups with large and small
numbers of tumour-infiltrating immune cells.
Patients with high numbers of peritumoural infiltration
of CD20+ B-lymphocytes in metastatic lymph nodes had a
significantly better outcome: DFS rates at 5 years were
100% vs. 64% for patients with a high versus low peritu-
moural accumulation (>192 CD20+ cells vs. <192 CD20+
per 0.087 mm2, p = 0.04) (figure 2A).
An increased intraepithelial infiltration of CD8+-TIL
(>1.29 CD8+ TIL LI) in metastatic lymph nodes was asso-
ciated with a superior DFS rate of 91% vs. 53% (p = 0.07)
(Figure 2B).
There was a trend towards improved DFS rates for patients
with an increased infiltration of FoxP3+-TIL in the primary
tumour (Figure 2C) with 86% vs. 63% (p = 0.27) as well
as FoxP3+-TIL in N+ nodes with 84% vs. 53% (p = 0.17).
A similar though again statistically not significant result
was found for the impact of peritumoural FoxP3+ lym-
phocytes in metastatic lymph nodes: DFS rates at 5 years
were 91% vs. 62% (p = 0.18) (table 3).BMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
Page 5 of 10
(page number not for citation purposes)
The infiltration of the primary tumour by CD3+, CD8+,
CD20+, CD68+ and Granzyme B+ had only limited influ-
ence on DFS (Table 3). Similarly, an analysis of the ratios
of leukocyte subsets over FoxP3+-TIL did not reveal any
influence on prognosis (not shown).
Discussion
Tumour infiltrating lymphocytes are generally considered
to represent host immunity against tumours [1,2]. Evi-
dence to support this notion mainly comes from clinical
studies showing that in certain tumour models, large
numbers of CD8+ TIL are associated with a favourable out-
come [3-6]. However, this is not applicable to all tumour
models. Thus, cytotoxic TILs were found to have a nega-
tive effect on patients' prognosis in anal cancer or Hodg-
kin lymphoma [23,24]. The discovery of Treg has further
complicated this issue. As anticipated, tumour infiltrating
FoxP3+ Treg have been reported to be negative prognostic
Table 2: Median, range and mean labeling index for different immune cells (CD3+, CD8+, CD20+, CD68+, FoxP3+, Granzyme B+) 
within primary tumor, metastatic lymph nodes and uninvolved regional lymph nodes
TIL Primary-
tumor
Intraepithelial N+ node Peritumoral N+ node Non-metastatic node
cells per 100 tumor cells cells per image (0.087 mm2)
CD3
Median (range) 3.04
(0–19)
3.52
(0.16–13.52)
204.5
(60–341)
183
(54–348)
Mean ± SE 4.36 ± 4.92 4.34 ± 4.64 209.1 ± 68.5 183.4 ± 69.3
CD8
Median (range) 2.49
(0.19–17.79)
1.29
(0.16–16.23)
37.5
(10–149)
88
(25–308)
Mean ± SE 3.54 ± 4.48 3.31 ± 4.71 45.8 ± 37.5 108.5 ± 69.8
CD20
Median (range) 0.23
(0.11–5.26)
1.76
(0.15–5.22)
192
(19–631)
148.5
(14–321)
Mean ± SE 0.91 ± 1.48 2.53 ± 2.93 200.6 ± 124.3 148.9 ± 83.9
CD68
Median (range) 1.02
(0.15–5.22)
1.05
(0–4.93)
5.5
(1–17)
4
(1–23)
Mean ± SE 1.17 ± 1.26 1.37 ± 1.26 6.5 ± 4.7 7 ± 6.2
FoxP3
Median (range) 1.81
(0.15–13.0)
2.26
(0.32–18.4)
44
(4–134)
49.5
(10–139)
Mean ± SE 2.88 ± 2.90 2.96 ± 3.29 49.0 ± 33.2 53.6 ± 26.4
Granzyme B
Median (range) 1
(0–21)
0
(0–10)
0
(0–54)
3
(0–39)
Mean ± SE 2.03 ± 3.93 1.39 ± 2.70 4.79 ± 11.52 5.27 ± 7.96BMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
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Mean labeling index of TIL-subsets in the different compartments Figure 1
Mean labeling index of TIL-subsets in the different compartments. Intraepithelial in primary tumor and N+ nodes (A) 
as well as mean infiltration in peritumoral lymphatic tissue and non- metastatic nodes (B). Mean TIL/CD3 Ratio in the different 
compartments (C). * p < 0.05, ** p < 0.01.BMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
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factors for ovarian, esophageal and hepatocellular cancer
[25-27]. Again, however, other studies have demonstrated
different effects. Thus, FoxP3+ Tregs were associated with
favourable prognosis in patients with Hodgkin or follicu-
lar lymphoma as well as in HNSCC patients [16,24,28],
while no effect was reported for anal carcinomas [23].
Moreover, it has been suggested that absolute numbers
may be less relevant than TIL subset ratios. For example,
low numbers of Treg together with large numbers of cyto-
toxic T-cells have been demonstrated to indicate favoura-
ble outcome in ovarian cancer while the same
constellation is indicative of poor prognosis in Hodgkin
lymphoma [6,24].
In addition to these issues, a few studies have begun to
address the question of heterogenity of immunological
microenvironments in primary carcinoma, lymph node
metastases and uninvolved regional lymph nodes. This is
important since it has been suggested that many solid can-
cers may be invisible to the immune system at the primary
site and are only recognised following metastasis into
regional lymph nodes [8,29].
HNSCC represent a heterogenous group of tumours char-
acterised by squamous differentiation and includes
tumours arising at diverse anatomical sites such as oral
mucosa and palatine tonsils. Our study was restricted to
carcinomas arising in the oro- and hypopharynx in order
to minimise site-related variability. It has become clear in
recent years, that a substantial proportion of HNSCC are
associated with human papillomavirus (HPV). Overall,
up to 20% of HNSCC are HPV-positive [12]. However, the
rate of positivity varies depending on site with highest
numbers of HPV-positive cases being observed in the
oropharynx [12]. We used p16 expression as a surrogate
marker of HPV infection. p16 expression was found in
31% of cases, in keeping with the high proportion of
oropharyngeal carcinomas in our series. It has been
shown recently, that HPV-associated HNSCC differ from
the HPV-negative cases with regards to risk factors and
notably are not associated with smoking [30]. It is likely,
that HPV status of tumour cells and concomitant expres-
sion of viral proteins will affect the nature of local
immune reactions. This will have to be addressed in future
studies.
We have investigated the distribution of tumour infiltrat-
ing leukocytes in tumour-related compartments of
HNSCC. We firstly show that, as a proportion of CD3-pos-
itive T-cells, the composition of T-cell subsets within pri-
mary and metastatic carcinomas varies from that seen in
adjacent lymph node tissue. Notably, we confirm previ-
ous studies reporting an increase in the proportion of
FoxP3-positive Treg and of cytotoxic T-cells among TILs
[2]. This observation supports the notion that tumour
cells actively modulate their microenvironment, possibly
by the expression of cytokines and chemokines.
We also show that the numbers of tumour infiltrating
CD3+ T-cells, CD8+ and GranzymeB+ cytotoxic T-cells as
well as of FoxP3+ Treg are similar in primary HNSCC and
in lymph node metastases. A notable exception were
CD20+  intratumoural B-cells which were significantly
more frequent in metastatic deposits than in primary
Impact of different TIL subgroups in various compartments on NED-survival rates Figure 2
Impact of different TIL subgroups in various compartments on NED-survival rates. Impact of CD20+ – lymphocyte 
infiltration of peritumoral lymphatic tissue(A), impact of intraepithelial CD8+-TIL in N+ nodes (B) and impact of FoxP3+-TIL 
infiltration of primary tumor (C).BMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
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Table 3: Impact of infiltration by various immune cell subtypes on disease-free survival (DFS)
Cut-off value* DFS p
Immune cells in primary tumor
CD3 >3.04 (n = 16) vs. ≤ 3.04 (n = 16) 85% vs. 67% 0.4
CD8 >2.49(n = 16) vs. ≤ 2.49(n = 16) 79% vs. 69% 0.29
FoxP3 >1.81 (n = 17) vs. ≤ 1.81(n = 15) 86% vs. 63% 0.27
CD20 >0.23 (n = 18) vs. ≤ 0.23(n = 13) 83% vs. 81% 0.8
CD68 >1.02 (n = 16) vs. ≤ 1.02(n = 16) 73% vs. 75% 0.8
Granzyme B >0 (n = 18) vs. = 0(n = 15) 82% vs. 68% 0.53
Intraepithelial immune cells in metastatic lymph nodes
CD3 >3.52 (n = 13) vs. ≤ 3.52 (n = 14) 77% vs. 62% 0.26
CD8 >1.29 (n = 14) vs. ≤ 1.29 (n = 14) 91% vs. 53% 0.07
FoxP3 >2.26 (n = 14) vs. ≤ 2.26 (n = 13) 84% vs. 53% 0.17
CD20 >1.76 (n = 12) vs. ≤ 1.76 (n = 11) 82% vs. 60% 0.29
CD68 >1.05 (n = 14) vs. ≤ 1.05 (n = 13) 67% vs.73% 0.9
Granzyme B >0 (n = 11) vs. = 0(n = 19) 80% vs. 68% 0.46
Peritumoral immune cells in lymphatic tissue of metastatic nodes
CD3 >204.5 (n = 13) vs. ≤ 204.5 (n = 13) 66.7% vs. 80.8% 0.25
CD8 > 37.5 (n = 12) vs. ≤ 37.5 (n = 12) 72.7% vs. 76.4% 0.53
FoxP3 > 44 (n = 11) vs. ≤ 44 (n = 12) 90.9% vs. 62.3% 0.18
CD20 > 192 (n = 11) vs. ≤ 192 (n = 11) 100% vs. 63.6% 0.039
CD68 > 5.5 (n = 13) vs. ≤ 5.5 (n = 13) 76.9% vs. 81.5% 0.5
Granzyme B >0 (n = 15) vs. = 0 (n = 15) 78.6% vs.67.3% 0.65
Immune cells in uninvolved regional lymph nodes
CD3 >183 (n = 15) vs. ≤ 183 (n = 16) 75.0% vs. 73.3% 0.675
CD8 >88 (n = 15) vs. ≤ 88 (n = 16) 84.6% vs. 65.6% 0.337
FoxP3 >49 (n = 15) vs. ≤ 49 (n = 16) 78.6% vs. 71.1% 0.905
CD20 >147 (n = 15) vs. ≤ 147 (n = 16) 79% vs. 68.6% 0.779
CD68 >4 (n = 12) vs. ≤ 4 (n = 17) 75.8% vs. 68.8% 0.424
Granzyme B >0 (n = 13) vs. = 0 (n = 15) 73.3% vs.68.8% 0.939
*Median was used as cut-offBMC Cancer 2009, 9:292 http://www.biomedcentral.com/1471-2407/9/292
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tumours. While we cannot prove that the immunoglobu-
lins expressed by these B-cells are specific for antigens
expressed in the tumours, this observation is in keeping
with the notion that a relevant interaction between
tumours and the humoral immune system occurs in
lymph nodes rather than at the primary tumour site.
Furthermore, a significant reduction of CD8+-lym-
phocytes in peritumoural areas in metastatic lymph nodes
as compared to uninvolved regional lymph nodes was
observed. This finding is in agreement with previous stud-
ies of head and neck as well as breast cancers and suggests
a general suppression of cytotoxic T cell immunity in the
immediate vicinity of the neoplastic cells [11,31,32]. It
has been suggested that a cytokine-induced local shift
towards a Th2-predominant pattern of immunity may
enable tumours to avoid host immunity [33], and our
observation is in line with this notion.
To assess the significance of the differential accumulation
of TIL subsets, we examined the effect on DFS in our
patients. Large numbers of intraepithelial CD8+  TIL
tended to be associated with a favourable outcome. This
effect was stronger for metastatic lymph node deposits
than for primary tumours, although neither reached sta-
tistical significance, probably due to the relative small
number of cases. Nevertheless, this observation is well in
line with previous studies of other solid malignancies [3-
6].
Patients with large numbers of CD20+ B-cells generally
also showed favourable outcome. There were however,
clear differences when analysing different compartments.
No effect was seen in primary tumours, while a statisti-
cally significant improvement of DFS was noted in those
patients showing large numbers of CD20+ cells in the per-
itumoural lymphoid tissue in metastatic lymph nodes.
Again, this observation underlines the potentially impor-
tant role of B-cells in anti-tumour immunity.
All other leukocyte subsets, including FoxP3+ Treg, did not
show any significant influence on outcome. This was
unexpected since several previous studies have suggested
an adverse prognostic effect of Treg in ovarian carcinoma
and HNSCC [25]. However, in other malignancies oppo-
site effects have been observed, and our previous study of
anal carcinomas has not shown a significant prognostic
influence of Treg [23]. Thus, the role of Treg in anti-
tumour immunity is likely to be heterogeneous. In addi-
tion, it is becoming increasingly clear that FoxP3 expres-
sion is not restricted to Treg. Indeed, FoxP3 expression has
been demonstrated in normal and neoplastic epithelial
cells. Since in our cases the tumour cells were consistently
FoxP3-negative, this did not interfere with the interpreta-
tion of our results. In addition, regulatory functions in
tumour immunity may not be restricted to FoxP3-positive
Treg and includes certain myeloid-derived cells [2]. Thus,
a comprehensive analysis of the clinical impact of
immune cells with regulatory function in HNSCC will
have to include cell populations in addition to Treg as
defined by FoxP3 expression.
Conclusion
In conclusion, we show that patterns of tumour-related
leukocyte infiltration vary between primary tumours and
metastatic lymph nodes in head and neck cancers with a
local decrease in the number of CD8+ T-cells and an
increase of CD20+ B-cells being the most relevant find-
ings. The notion that a suppression of local cellular
immunity may be a strategy by which tumours may evade
host immunity [33] is supported by our observation that
patients with large numbers of intraepithelial CD8+ cells
in metastatic tumour deposits showed a more favourable
outcome. Unxpectedly, we also found a beneficial effect of
large numbers of CD20-positive B-cells in metastatic
lymph nodes suggesting an important role for humoral
anti-tumour immunity.
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